Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Geoffrey von Maltzahn
AddedFeb 13, 2024
UpdatedJun 26, 2026
Geoffrey von Maltzahn

Geoffrey von Maltzahn

Co-Founder & Chief Executive Officer, Lila Sciences· 2023 – present · 3 yrs

CrunchbaseLinkedInThe Org

Geoffrey von Maltzahn's Career

Lila Sciences
Lila Sciences

Cambridge, MA, US

Co-Founder & Chief Executive Officer
2023 – present · 3 yrs
Kaleido Biosciences
Kaleido Biosciences

Lexington, MA, US

Co-Founder
Generate Biomedicines
Generate Biomedicines

Somerville, MA, US

Board Member· Board
Indigo
Indigo

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Geoffrey von Maltzahn's Career

Lila Sciences
Lila Sciences
Series A$550M4492023Cambridge, MA, US
Co-Founder & Chief Executive Officer
2023 – present · 3 yrs

Recent news

Building the Agent-Driven Era of Science with NVIDIA BioNeMo Agent ToolkitLila Sciences · 2026
Lila Sciences Named No. 25 on the 2026 CNBC Disruptor 50 ListCNBC · 2026
Announcing Lila's $350M Series A and Incredible Partners on Our MissionLila Sciences · 2025

Leadership at Lila Sciences

Christopher FussellChristopher FussellPresident, Operations
Jonathan HennekJonathan HennekChief Revenue & Product Officer
John GregoireJohn GregoireChief Autonomous Science Officer
Rafael Gomez-BombarelliRafael Gomez-BombarelliCSO, Physical Sciences
Julie ShahJulie ShahChief Robotics Officer
Andrew BeamAndrew BeamChief Technology Officer

Similar to Lila Sciences

Insilico MedicineInsilico MedicineNew York City, NY, USDrug Discoveryest. 2014Insilico MedicineNew York City, NY, US · est. 2014

Insilico Medicine: A global AI biotech firm dedicated to extending human productive longevity.

Series D · $401.3M278
Recursion PharmaceuticalsRecursion PharmaceuticalsSalt Lake City, UT, USPharmaceuticalsest. 2013Recursion PharmaceuticalsSalt Lake City, UT, US · est. 2013

Recursion Pharmaceuticals: An American company innovating hereditary disease treatments.

Public · $665.4M500
QuadrillionQuadrillionNew York, NY, USest. 2025QuadrillionNew York, NY, US · est. 2025

Quadrillion builds Qualia, an AI research-agent platform for notebook-based data science workflows.

Seed · $7M9
FluidizeFluidizeSan Francisco, CA, USest. 2025FluidizeSan Francisco, CA, US · est. 2025

Fluidize is an AI platform that accelerates scientific R&D by automating simulation and experiment workflows for scientists and engineers.

Seed · $500k3
Kaleido Biosciences
Kaleido Biosciences
Public$230.9M762015Lexington, MA, US
Co-Founder

Leadership at Kaleido Biosciences

Alison LawtonAlison LawtonBoard Member
Theo Melas-KyriaziTheo Melas-KyriaziBoard Member
Anthony QuinnAnthony QuinnBoard Member
Mike BonneyMike BonneyBoard Member
Jean MixerJean MixerBoard Member
R Grady BurnettR Grady BurnettBoard Member
Generate Biomedicines
Generate Biomedicines
Series C$693M3102018Somerville, MA, US
Board Member· Board

Leadership at Generate Biomedicines

Noubar AfeyanNoubar AfeyanCo-Founder
Gevorg GrigoryanGevorg GrigoryanCo-Founder
Mike NallyMike NallyBoard Member
Molly GibsonMolly GibsonCo-Founder
Sophie de BoerSophie de BoerCo-Founder
Indigo
Indigo
Late Stage Private$1.4B1.7k2013Boston, MA, US
Board Member· Board

Leadership at Indigo

David PerryDavid PerryBoard Member
John GehringJohn GehringBoard Member
Peter InnesPeter InnesBoard Member
Ann SimondsAnn SimondsBoard Member
David BerryDavid BerryCo-Founder
Ron HovsepianRon HovsepianBoard Member

Similar to Indigo

CortevaCortevaIndianapolis, IN, USCrop Protection, Seedest. 2019CortevaIndianapolis, IN, US · est. 2019

Corteva Agriscience, an American agriculture company, innovatively delivers solutions for global agriculture challenges, maximizing farmer productivity.

Public21k
Advancing Eco AgricultureAdvancing Eco AgricultureMiddlefield, OH, USAgriculture, Productsest. 2006Advancing Eco AgricultureMiddlefield, OH, US · est. 2006

Advancing Eco Agriculture: Balancing yield inputs for regenerative agriculture systems.

Series A · $4.7M68
Sound AgricultureSound AgricultureEmeryville, CA, USCrop Solutionsest. 2012Sound AgricultureEmeryville, CA, US · est. 2012

Sound Agriculture: Innovating crop solutions for climate-resilient farming and enhanced yields, US-based.

Series D · $170.4M168
Pivot BioPivot BioBerkeley, CA, USAgricultural Productsest. 2010Pivot BioBerkeley, CA, US · est. 2010

Pivot Bio, Inc.: A US-based AgriTech firm innovating plant nutrition by harnessing atmospheric nitrogen.

Series D · $616.9M488

Geoffrey von Maltzahn's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Geoffrey von Maltzahn

Ephraim HellerEphraim HellerBoard Member · SynAgileWarren Seymour JohnsonWarren Seymour JohnsonFounder · Johnson ControlsRobert GottschalkRobert GottschalkCo-Founder · PanavisionChuck HullChuck HullFounder · 3D SystemsKurt PetersenKurt PetersenAmerican inventorTim JenisonTim JenisonFounder · NewTek